Novo Nordisk’s obesity drug Wegovy was approved in China on Tuesday, though the company has not announced launch plans and starter doses in the U.S. have been in short supply for months.

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk NOVO.B3.06%increase; green up pointing triangle to begin selling it in the world’s second ...

Wegovy was just approved in China. Novo Nordisk (NVO-1.39%) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1 ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

China’s National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one ...

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest ...

Some analysts expect Zepound, the U.S. firm’s weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025.

Alongside Novo Nordisk's Wegovy, China's medicines regulator has also approved two other GLP-1 weight-loss drugs including Huadong Medicine's Liluping and Benemae Pharmaceutical Corporation's drug ...

China has approved Novo Nordisk A/S’s blockbuster Wegovy for chronic weight management, opening up competition for next-generation obesity drugs in the world’s second-largest economy.

SHANGHAI (Reuters) -Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the ...

Some analysts expect Zepound, the U.S. firm's weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025. Sponsored Bank Accounts ...